Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Loic Ysebaert, Emmanuelle Ferrant, Marie Sarah Dilhuydy, Anne-Sophie Michallet, Luca Inchiappa, Romain Guieze, Emmanuelle Tchernonog, Ana Cavillon, Marie Christine Bene, Luc-Matthieu Fornecker

Blood (2023) 142 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2023-180696

Published: 2023

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Pre-Graft Vaccination or Infection Do Not Provide More Protection Against COVID-19 Infections in Post-Graft Vaccinated Recipients of Allogeneic Stem Cell Transplantation

Valentin Letailleur, Amandine Le Bourgeois, Thierry Guillaume, Alice Garnier, Pierre Peterlin, Maxime Jullien, Chloe Antier, Marie-Christine Béné, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 4941.

https://doi.org/10.1182/blood-2023-179991

Published: 2023

Journal Articles

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

Yannick LE Bris, Romain Madeuf, Catherine Godon, Olivier Pichon, Pierre Peterlin, Alice Garnier, Patrice Chevallier, Simon Bouzy, Marion Eveillard, Marie-Christine Béné, Olivier Theisen, Faeseh vasheghani Farahani

Blood (2023) 142 (Supplement 1): 6051.

https://doi.org/10.1182/blood-2023-188581

Published: 2023

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

Therapeutic Targets in Childhood B-Acute Lymphoblastic Leukemia : What about HER2/Neu?

Margaux Camuset, MD, Alice Huault, Audrey Grain, MD, Beatrice Clemenceau, PhD, Fanny Rialland, MD, Caroline Thomas, MD, Patrice Chevallier, MD PhD, Marie-Christine Béné, PharmSciD, PhD, Marion Eveillard

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140273

Published: 2020

Journal Articles

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Sylvain Garciaz, Marie Anne Hospital, Colombe Saillard, MD, Yosr Hicheri, Evelyne D'Incan, Jerome Rey, Catherine Lacombe, Arnaud Pigneux, MD PhD, Marie-Christine Béné, PharmSciD, PhD, Christian Recher, MD PhD, Marie-Joelle Mozziconacci, Norbert Vey, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141229

Published: 2020

Journal Articles

Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 5771.

https://doi.org/10.1182/blood-2019-122958

Published: 2019

Journal Articles

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Blood (2019) 134 (Supplement_1): 1985.

https://doi.org/10.1182/blood-2019-122013

Published: 2019

Journal Articles

A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients

Blood (2019) 134 (Supplement_1): 1412.

https://doi.org/10.1182/blood-2019-125774

Published: 2019

Journal Articles

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Frederic Picou, PhD, Jean-Claude Chomel, PharmD PhD, Marie Christine Bene, PharmD, Marc G. Berger, MD PhD, Thierry Fest, Valerie Ugo, MD PhD, Eric Lippert, MD PhD, Marion Socco-Luca, Martine Delain, MD, Marie-Helene Estienne, PharmD, Olivier Herault, MD PhD

Blood (2018) 132 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2018-99-118297

Published: 2018

Journal Articles

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2018) 131 (12): 1275–1291.

https://doi.org/10.1182/blood-2017-09-801498

Published: 2018

Includes: Supplemental data

Journal Articles

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

David Gottlieb, MBBS MDFRACP FRCPA, Thérèse Aurran, MD, Constantine S. Tam, MD, Mary Sartor, PhD, Rémi Letestu, MD PhD, Dennis Carney, Gavin Cull, MBBS DM FRACP FRCPA, Vincent Levy, MD PhD, Veronique Leblond, MD PhD, Marie Christine Bene, Andrew Budniak, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Florence Cymbalista, MD PhD

Blood (2016) 128 (22): 2053.

https://doi.org/10.1182/blood.V128.22.2053.2053

Published: 2016

Journal Articles

In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Beatrice Clemenceau, PhD, Thierry Guillaume, MD PhD, Nelly Robillard, PhD, Regine Vivien, Pierre Peterlin, MD, Alice Garnier, MD, Marie-Christine Bene, Henri Vié, PhD, Patrice Chevallier, MD PhD

Blood (2016) 128 (22): 5193.

https://doi.org/10.1182/blood.V128.22.5193.5193

Published: 2016

Journal Articles

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Blood (2016) 128 (22): 674.

https://doi.org/10.1182/blood.V128.22.674.674

Published: 2016

Journal Articles

Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

Blood (2016) 128 (22): 145.

https://doi.org/10.1182/blood.V128.22.145.145

Published: 2016

Journal Articles

A Phase I/II Study of Vaccination By Autologous Leukemic Apoptotic Corpse Pulsed Dendritic Cells for Elderly Acute Myeloid Leukemia Patients in First or Second Complete Remission (LAM DC trial)

Patrice Chevallier, MD PhD, Soraya Saiagh, Virginie Dehame, MSc, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Yannick Le Bris, PharmD, Sylvain Bercegeay, Delphine Coulais, Marie-Aude Rambaud, Céline Bossard, MD, Veronique Stocco, MD, Brigitte Dreno, MD PhD, Nadine Juge-Morineau, MD, Philippe Moreau, Marie-Christine Bene, PharmD, Marc Gregoire, PhD

Blood (2016) 128 (22): 2821.

https://doi.org/10.1182/blood.V128.22.2821.2821

Published: 2016

Journal Articles

Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study

Blood (2015) 126 (23): 1.

https://doi.org/10.1182/blood.V126.23.1.1

Published: 2015

Journal Articles

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Eve Poret, Fanny Angelot Delettre, Sabeha Biichle, Anne Roogy, Louis Benazet, Maider Pagadoy, Chrystelle Vidal, Franck Leroux, Véronique Harrivel, Christophe Ferrand, PhD, Veronique Salaun, Zehaira Benseddik, Julien Guy, Marie Christine Jacob, Christophe Roumier, Jean Feuillard, Liliana Vila, Lucile Baseggio, Adriana Plesa, Christine Arnoulet, B Benet, Bernard Drenou, MD, Veronique Latger Cannard, Marie-Christine Bene, MD, Michel Ticchioni, Daniel Lusina, Valerie Bardet, Magalie LE Garff Tavernier, Elizabeth Macintyre, MD PhD, Vahid Asnafi, MDPhD, Maria Elena Noguera, Sabrina Bouyer, Carine Lecoq Lafon, Mikael Roussel, MD PhD, Fabrice Jardin, Francoise Solly, MD, Lydia Campos, MD PhD, Anne Galoisy, Anne Arnaud, Sylvie Daliphard, Franck Genevieve, MD PhD, Romaric Lacroix, Françoise Schillinger, Estelle Seilles, Delphine Binda, Eric Deconinck, Philippe Saas, PhD, Francine Garnache Ottou, PhD

Blood (2015) 126 (23): 3812.

https://doi.org/10.1182/blood.V126.23.3812.3812

Published: 2015

Journal Articles

Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier

Patrice Chevallier, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Maud Voldoire, MD, Thomas Gastinne, MD, Cyrille Touzeau, MD PhD, Steven Le Gouill, MD PhD, Marie-Christine Bene, MD, Yannick LE Bris, PharmD, Philippe Moreau, Thierry Guillaume, MD PhD

Blood (2015) 126 (23): 5519.

https://doi.org/10.1182/blood.V126.23.5519.5519

Published: 2015

NARROW

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Pre-Graft Vaccination or Infection Do Not Provide More Protection Against COVID-19 Infections in Post-Graft Vaccinated Recipients of Allogeneic Stem Cell Transplantation

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Therapeutic Targets in Childhood B-Acute Lymphoblastic Leukemia : What about HER2/Neu?

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

A Phase I/II Study of Vaccination By Autologous Leukemic Apoptotic Corpse Pulsed Dendritic Cells for Elderly Acute Myeloid Leukemia Patients in First or Second Complete Remission (LAM DC trial)

Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only